Loading…
Loading…
EQUITY / NASDAQ · XNAS
BioStem Technologies, Inc.
01 / RESEARCH
8 financial reports are available for research.
Start research ↗3.25 USD · 5.178%
Observed: Sep 30, 2026, 11:58 PM · TickerLayer indicative price; may be delayed
Powered by TickerLayer
09/30/2026 · 3.09 USD · Volume 332,920
21 actual observations · Latest bar: 2026-09-30 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | Prior year | Change |
|---|---|---|---|
| Cash and cash equivalents | 6,962,492 USD | — | — |
| Gross profit | 4,840,661 USD | — | — |
| Net income | -8,971,360 USD | — | — |
| Operating profit | -8,400,687 USD | — | — |
| Revenue | 7,899,249 USD | — | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 2ConsolidatedUnits · USD | 2026 / Quarter 2ConsolidatedUnits · USD | 2026 / Quarter 2ConsolidatedUnits · USD | 2026 / Quarter 2ConsolidatedUnits · USD | 2026 / Quarter 2ConsolidatedUnits · USD | 2026 / Quarter 2ConsolidatedUnits · USD | 2026 / Quarter 2ConsolidatedUnits · USD | 2026 / Quarter 2ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 6,962,492 USD | — | — | 29,549,018 USD | — | — | — | — |
| Gross profitIncome statement | 4,840,661 USD | 8,600,152 USD | — | — | 10,277,997 USD | 25,391,580 USD | — | — |
| Net incomeIncome statement | -8,971,360 USD | -17,791,065 USD | — | — | 10,613 USD | 3,918,735 USD | — | — |
| Operating profitIncome statement | -8,400,687 USD | -17,285,238 USD | — | — | 112,759 USD | 5,362,084 USD | — | — |
| RevenueIncome statement | 7,899,249 USD | 14,034,779 USD | — | — | 10,963,174 USD | 26,930,195 USD | — | — |
| Total assetsBalance sheet | 48,818,296 USD | — | — | 50,026,661 USD | — | — | — | — |
| Total equityBalance sheet | 27,614,597 USD | — | 31,868,633 USD | 39,137,819 USD | 47,234,761 USD | — | 46,091,283 USD | 40,021,924 USD |
| Total liabilitiesBalance sheet | 21,203,699 USD | — | — | 10,888,842 USD | — | — | — | — |
| Capital expendituresCash flow statement | — | 57,925 USD | — | — | — | 497,150 USD | — | — |
| Financing cash flowCash flow statement | — | -1,146,253 USD | — | — | — | -988,017 USD | — | — |
| Investing cash flowCash flow statement | — | -15,076,296 USD | — | — | — | -497,150 USD | — | — |
| Operating cash flowCash flow statement | — | -6,363,977 USD | — | — | — | 9,496,341 USD | — | — |
| Report source | Open report ↗ Published: 08/12/2026 | Open report ↗ Published: 08/12/2026 | Open report ↗ Published: 08/12/2026 | Open report ↗ Published: 08/12/2026 | Open report ↗ Published: 08/12/2026 | Open report ↗ Published: 08/12/2026 | Open report ↗ Published: 08/12/2026 | Open report ↗ Published: 08/12/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.